QCDx is a medical company developing advanced liquid biopsy technologies to detect and profile rare circulating tumor cells (CTCs) for precision oncology and therapeutic drug development. Our mission is to uncover CTC heterogeneity in both early-stage and advanced disease, enabling precise cancer diagnosis that empowers oncologists to optimize treatment strategies, monitor therapy, characterize metastasis, and assess treatment toxicity—ultimately improving patient outcomes and quality of life.